Loading patent…
OwnerRubén Alvarez Sánchez, Roberto Iacone +8inventors
InventorsRubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
Estimating the term…
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
(canceled)
A method for treating macular degeneration or diabetic retinopathy, the method comprising intraocular administration of an oligonucleotide of 10-30 nucleotides in length which is complementary to SEQ ID NO:
A single-strand oligonucleotide of 10-30 nucleotides in length which is complementary to SEQ ID NO:
Dependencies are inferred from the claim text.